RxDoctor Payments Data

Khaldun Khatib

Gastroenterology · Greenville, TXNPI 1235352899

Payments from drug & device makers

$2,358in general payments, 2019–2025

Across 135 payments — averaging $17.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Endogastric Solutions, Inc$940
  • AbbVie$705
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$118
  • Johnson & Johnson$90
  • Takeda Pharmaceuticals U.S.A., Inc.$89
  • Pfizer$88
  • plus $328 from 12 others

What the payments were for

  • Travel & lodging$78733%
  • Food & beverage$1,54065%
  • Education$311%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,358 in reported general payments places this provider in the 40th percentile of 1,350 gastroenterology providers in Texas.

See all gastroenterology providers in Texas

Medicare billing

Part B allowed, 2024
$151,892
Medicare patients
593
Services billed
1,179

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab19$548,046
LinzessLinaclotide182$133,222
RezdiffraResmetirom26$112,542
XifaxanRifaximin26$84,051
TrulancePlecanatide74$55,214
Dexlansoprazole DrDexlansoprazole150$36,792
ZenpepLipase/Protease/Amylase13$19,285
MotegrityPrucalopride Succinate35$18,637
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates259$14,356
ClenpiqSod Picosulf/Mag Ox/Citric Ac42$7,440
Lubiprostone95$7,212
Mesalamine19$6,277
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C45$6,204
Esomeprazole Magnesium116$5,453
Budesonide DrBudesonide29$4,827

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$90$548,04619 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance, Plenvu$118$145,469145 claims
AbbVieLinzess$705$133,222182 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$89$18,63735 claims
Ferring Pharmaceuticals Inc.Clenpiq$17$7,44042 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,350 gastroenterology providers in Texas.

Other gastroenterology in Greenville

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →